2018-16292. National Cancer Institute; Notice of Closed Meeting  

  • Start Preamble

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

    The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the Start Printed Page 36945proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis Panel; JUN2018 Cycle 29 NExT SEP Committee Meeting.

    Date: August 30, 2018.

    Time: 8:00 a.m. to 4:30 p.m.

    Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio.

    Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Wing C, 6th Floor, Conference Room 6, Bethesda, MD 20892.

    Contact Persons: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817, (301) 496-4291, mroczkoskib@mail.nih.gov. Toby Hecht, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 3W110, Rockville, MD 20850, (240) 276-5683, toby.hecht2@nih.gov.

    (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

    Start Signature

    Dated: July 25, 2018.

    Melanie J. Pantoja,

    Program Analyst, Office of Federal Advisory Committee Policy.

    End Signature End Preamble

    [FR Doc. 2018-16292 Filed 7-30-18; 8:45 am]

    BILLING CODE 4140-01-P

Document Information

Published:
07/31/2018
Department:
Health and Human Services Department
Entry Type:
Notice
Document Number:
2018-16292
Dates:
August 30, 2018.
Pages:
36944-36945 (2 pages)
PDF File:
2018-16292.pdf